Aristides Capital LLC Phathom Pharmaceuticals, Inc. Transaction History
Aristides Capital LLC
- $260 Million
- Q4 2024
A detailed history of Aristides Capital LLC transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Aristides Capital LLC holds 25,200 shares of PHAT stock, worth $157,752. This represents 0.08% of its overall portfolio holdings.
Number of Shares
25,200Holding current value
$157,752% of portfolio
0.08%Shares
1 transactions
Others Institutions Holding PHAT
# of Institutions
158Shares Held
68.6MCall Options Held
52.3KPut Options Held
635K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$63.3 Million4.92% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$46.7 Million13.31% of portfolio
-
Jennison Associates LLC7.06MShares$44.2 Million0.04% of portfolio
-
Invesco Ltd. Atlanta, GA3.67MShares$23 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$21.9 Million28.4% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $245M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...